Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
The de-extinction startup is looking to double or triple its previous valuation, according to the report.
Colossal Biosciences is reportedly in discussions to raise fresh capital at a valuation between $20 billion and $30 billion, according to a TechCrunch report. If completed at that range, the deal would represent a sharp increase from the company’s previous valuation, potentially doubling or tripling it.
The startup, known for its de-extinction work, has attracted attention for an ambitious scientific approach that sits at the intersection of biotechnology and conservation. The latest fundraising talk, as described in the monitored public feed, suggests continued investor interest in the company despite the unusually high valuation range.
No additional deal terms were included in the feed summary, and it was not clear how far along the discussions are or how much capital Colossal may be seeking to raise. The report also did not provide details on participating investors or a timeline for any potential transaction.
Colossal has become one of the most closely watched companies in biotech, in part because of the scale of its scientific goals and the financing needed to support them. A valuation in the $20 billion to $30 billion range would place it among the most highly valued private companies in the sector, if the reported talks lead to a deal.
This article is based on a monitored public feed and summarizes the information made available there. Source attribution: TechCrunch.
Source: TechCrunch - https://techcrunch.com/2026/07/20/colossal-biosciences-reportedly-in-talks-to-raise-new-capital-at-20b-30b-valuation/
